<DOC>
	<DOC>NCT01015430</DOC>
	<brief_summary>This randomized, double-blind multiple ascending dose study will evaluate the safety and tolerability, pharmacokinetics and efficacy of RO4917523 in patients with Fragile X Syndrome. The patients will be randomized to receive either active drug or placebo. The anticipated time on study treatment is 6 weeks. The target sample size is &lt;100 patients.</brief_summary>
	<brief_title>A Study With RO4917523 in Patients With Fragile X Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fragile X Syndrome</mesh_term>
	<criteria>Adult patients, 18 to 50 years of age Fragile X Syndrome IQ less than 75 Reliable caregiver Current psychosis or presumption of psychosis History of suicidal behavior or considered a high suicidal risk Severe selfinjurious behavior Any unstable medical condition other than Fragile X Syndrome (e.g. hypertension, diabetes) Current seizure disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>